Journal
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Volume 170, Issue -, Pages -Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.critrevonc.2022.103597
Keywords
Colorectal cancer; Immunotherapy; MMR; MMR deficiency; MSI; PD-1; PD-L1; Solid tumors; Tumor-agnostic therapy
Categories
Ask authors/readers for more resources
Alterations in short-repetitive DNA sequences, known as microsatellite instability (MSI), can reflect deficiencies in mismatch repair (MMR) system. The dMMR/MSI status can better predict the response to immune checkpoint inhibitors (ICIs) in patients with solid tumors. Tissue-agnostic evaluation of MSI-H/dMMR may become a standardized approach for selecting patient subgroups who may benefit from immunotherapy.
Alterations in short-repetitive DNA sequences, known as microsatellite instability (MSI), can reflect deficiencies in Mismatch Repair (MMR) system which represents a major player in DNA integrity maintenance. The incidence of MSI-H/dMMR has been shown to be variable depending on the tumor type. Several studies confirmed that dMMR/MSI status, although less frequent than PD-L1 expression, may better predict response to immunecheckpoint inhibitors (ICIs) in patients with solid tumors. In October 2016, the FDA granted pembrolizumab as breakthrough therapy for the treatment of non-CRC, MSI-H/dMMR tumors, providing, for the first time, a tumor-agnostic indication. In the next future, the tissue-agnostic evaluation of MSI-H/dMMR could become the common denominator for the immunotherapy treatment of patients with different advanced solid tumors, in order to select patient subgroups which may benefit from this therapy. In this Review we provided an overview of the main clinical studies describing the association between MSI-H/dMMR tumors and immunotherapy response.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available